*Denotes that all funding listed has been matched by Alex’s Lemonade Stand Foundation, increasing the donation to twice the amount shown.
See All Projects Co-funded With Alex's Lemonade Stand Foundation
Click here for research funding guidelines.
$62,500* for LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma
Michael Engel, MD/PhD - University of Utah, Salt Lake City
With our proposed experiments, we will confirm that SP-2577 kills T-AL/L cells isolated from patients and transplanted into mice. We will also devise tests that show SP-2577 “hits its target” (LSD1) and may predict which patients will respond to the drug.
$25,000* for Developing Targeted Immunotherapy Against Pediatric Acute Myeloid Leukemia
Dr. Melinda Biernacki, MD - Fred Hutchinson Cancer Research Center, Seattle, WA
To develop new T cell therapy for pediatric AML, we propose to identify AML-specific neoepitopes by merging state-of-the-art gene sequencing of leukemia-specific variants with established HLA-binding prediction algorithms and a highthroughput immune-reactivity screen.
$75,000* for Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma
Anthony Faber, PhD - Virginia Commonwealth University
Using a combination of pharmacogenomics, drug screening and gene expression data mining, we have developed a novel targeted therapy combination that is specific for MYCN-amplified neuroblastoma. The goal of this grant is to further develop a combination targeted therapy to treat high-risk neuroblastoma.
Click Here to Read Faber Proposal
$75,000* for Preclinical Development of ATR Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy
Timothy Gershon, M.D./Ph.D. - University of North Carolina
This proposal will investigate the therapeutic potential of targeting the DNA damage response protein ATR for medulloblastoma therapy, using a small molecule inhibitor, VE- 822, in novel, nanoparticle formulation (pVE-822). Radiation and chemotherapy significantly extend survival for most patients with medulloblastoma, but produce significant long-term neuro-cognitive side effects.
Click Here to Read Gershon Proposal
$75,000* for Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma
John Bushweller, PhD - University of Virginia, School of Medicine
Current treatment for childhood AML, T-ALL, and Ewing’s sarcoma is limited in efficacy and has profound long- term side-effects due to the use of traditional cytotoxic agents rather than targeted drugs inhibiting specific drivers of the diseases. A targeted agent which inhibits ERG, clearly a driver of these diseases, has the potential to improve both survival and quality of life for children with AML, T-ALL, and Ewing’s sarcoma.
Click Here to Read Bushweller Proposal
$50,000 for Clinical Trial at Miami Children’s Hospital
John Raghelb, M.D.
I Care I Cure’s funding facilitated the clinical trial for 10 children with recurrent brain cancer with an innovative and novel alternative method of giving chemotherapy directly to the site of the tumor. This study will determine if infusion of chemotherapeutic agents directly into brain fluid spaces is a safe and effective method of delivering chemotherapy treatment for children with recurrent malignant brain tumors.
$100,000* for Development of Targeted Leukemia Inhibitors Using Nanoparticle Delivery
Lucio Castilla, PhD - University of Massachusetts Medical School,
Research using the targeted therapy of soluble gold nanoparticles as inert and versatile scaffolds to deliver potent leukemia inhibitors aimed at eliminating cancer cells, while having a negligible impact in normal cells.
$100,000* for Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemia
Andre Nessenzweig, PhD - National Cancer Institute
Research based on DNA damage response proteins to target therapeutic intervention as an inhibitor. These interventions are directed at specific cells, pathways or proteins that are indicative of heightened points of vulnerability in cancers, without the use of broad spectrum approaches.
$53,000* for Development of a Pharmacodynamic Marker of EWS-FLII Activity to Aid in the Clinical Translation of Targeted Therapies for Ewings Sarcoma
Vanderbilt University; Patrick J. Grohar, M.D., PhD
Research for a new therapy that targets the dominant oncogene of Ewing Sarcoma, EWS-FLI1, to improve survival rates.
$53,000* for Development of a Novel Mer TKI for Treatment of ALL
Dr. Doug Graham - University of Colorado, Denver
Research of treatment for acute lymphoblastic leukemia (ALL) by targeting Mer signals (which have been shown to contribute to ALL) with biological agent UNC2025.
$53,000* for Treatment of Medulloblastoma
Margarita Gutova, M.D. - Beckman Research Institute of City of Hope
Research for a more effective treatment for medulloblastoma (MB), using neural stem cells that produce anti-cancer drugs localized directly to MB cells to limit toxicity.
$53,000* for Engineering the Lymph Node Environment with Therapeutic Vaccine Depots to Combat Neuroblastoma
Christopher M. Jewell, PhD - University of Maryland, College Park;
Research combining direct lymph node delivery and vaccines to generate immune responses to combat neuroblastoma.
$50,000* for Identification and Validation of New Therapeutic Targets in Pediatric Leukemia Through an Aneuploidy-based Synthetic Lethality Screen
Dana-Farber Cancer Institute; David Pellman, M.D.
Research of Trisomy 8, which is abnormal number of chromosomes, that is present in 15-20% of cases of AML and MDS. Data is being analyzed to determine which genes selectively kill trisomy 8 AML cell lines.
$50,000* for Development of An Innovative Treatment Strategy for Neuroblastoma and Other Pediatric Tumors: A Novel Phospholipid Ester Analogue and its Multifunctional Cancer-targeting Nanoconstruct
Mario Otto, M.D., PhD - University of Wisconsin-Madison
Study will look at the molecule NM404 to ascertain if NM404 can target and kill neuroblastoma cells or other forms of childhood cancer cells, and to evaluate if this compound could be a new potent treatment drug.
$50,000* for Development of Targeted Therapies in High Risk Childhood Acute Lymphoblastic Leukemia
The Children’s Hospital of Philadelphia; Sarah Tasian, M.D.
Research will focus on studying blood and bone marrow samples from children with certain types of high-risk Acute Lymphoblastic Leukemia (ALL) with the goal of improving our understanding of the functional consequences of specific genetic mutations. Through this work, she hopes to improve understanding of the critical biologic mechanisms involved in these leukemias to help identify new targeted therapies for children with high-risk ALL.
$40,000* for Mechanisms of Oncogenic Transformation by TLX1/HOX11
Mark Yat-fung Chiang, M.D., PhD - Regents of University of Michigan
To advance the understanding of the biology of TLX1-driven leukemogenesis so as to identify important genes that may lead to more effective and less toxic therapies as more than one third of ALL survivors suffer long-term consequences such as second cancers.
$40,000* for Targeted Polymeric Parthenolide Carriers to Treat Childhood AML
Danielle Benoit, PhD - University of Rochester
Research to develop more effective treatments for children with AML by employing a polymer delivery system that would increase the solubility of parthenolide (PTL). This would allow it to be used for leukemia therapy, as it is only soluble at around 1 mg/ml in aqueous solutions. Polymer nanoparticles used for loading a leukemia therapeutic have been successfully created and thoroughly analyzed in vitro for their potential as therapeutically relevant drug carriers in mice.
$40,000* for Targeting Polycomb-mediated Epigenetic Silencing in T cell Acute Lymphoblastic Leukemia
Emmanuel Volanakis, M.D. - Vanderbilt University Medical Center
Research to understand the molecular signals the allow leukemia cells to thrive at the expense of normal cells by observing certain signaling mechanisms.
$62,500* for Development of Childhood Leukemia Translational Research Program
Lewis B. Silverman, M.D. - Dana-Farber Cancer Institute
Research to identify, develop, and test novel treatments and outcomes for children and adolescents with ALL and AML.
$100,000 for Discovery of Inhibitors of MLL Fusion Proteins as Targeted Therapies for Pediatric Acute Leukemia
Alfred I DuPont Hospital for Children; Andrew Napper, PhD
Research of selective killing of leukemia cells with MLL fusions with a cell-penetrating AF4 peptide; study extended to leukemia engrafted in mice.
$40,000 for Targeted Polymeric Parthenolide Carriers to Treat Childhood AML
Your generous donation will fund our mission to fight cancer and help the children and their families endure their daily struggles.
I Care I Cure Childhood Cancer Foundation
P.O. Box 291386
Davie, FL 33329
Contact Mercedes Holston
Tax ID 27-1014887